C5 anticorps

N° du produit ABIN2191948

Détail du produit anti-C5 anticorps

Antigène: C5 (Complement Component 5 (C5))

Reactivité: Humain

Hôte: Souris

Clonalité: Monoclonal

Conjugué: Cet anticorp C5 est non-conjugé

Application: Western Blotting (WB), Immunoassay (IA)

Stérilité: 0.2 μm filtered

Clone: 557

Information d'application

Indications d'application: For Western blotting, dilutions to be used depend on detection system applied. It is recommended that users test the reagent and determine their own optimal dilutions. The typical starting working dilution is 1:50. For functional studies, in vitro dilutions have to be optimized in user's experimental setting.. 1

Restrictions: For Research Use only

Stockage

Buffer: PBS, containing 0.1 % bovine serum albumin.

Stock: 4 °C

Stockage commentaire: Product should be stored at 4 °C. Under recommended storage conditions, product is stable for at least one year. The exact expiry date is indicated on the label.

Références pour anticorps anti-C5 (ABIN2191948)

Kola, Baensch, Bautsch, Klos, Köhl: "Analysis of the C5a anaphylatoxin core domain using a C5a phage library selected on differentiated U937 cells." dans: Molecular immunology, Vol. 36, Issue 2, pp. 145-52, (1999) (PubMed).

Kola, Baensch, Bautsch, Hennecke, Klos, Casaretto, Köhl: "Epitope mapping of a C5a neutralizing mAb using a combined approach of phage display, synthetic peptides and site-directed mutagenesis." dans: Immunotechnology : an international journal of immunological engineering, Vol. 2, Issue 2, pp. 115-26, (1997) (PubMed).

Klos, Ihrig, Messner, Grabbe, Bitter-Suermann: "Detection of native human complement components C3 and C5 and their primary activation peptides C3a and C5a (anaphylatoxic peptides) by ELISAs with monoclonal antibodies." dans: Journal of immunological methods, Vol. 111, Issue 2, pp. 241-52, (1988) (PubMed).

Détails sur C5

Antigène: C5 (Complement Component 5 (C5))

Autre désignation: c5/c5a (C5 Produits)

Synonymes: anticorps C5, anticorps LOC565774, anticorps C5a, anticorps C5b, anticorps CPAMD4, anticorps Hc, anticorps RGD1561905, anticorps He, anticorps complement C5, anticorps complement component 5, anticorps hemolytic complement, anticorps C5, anticorps c5, anticorps Hc

Sujet: The monoclonal antibody 557 recognizes an epitope of complement factor 5 (C5) and C5a. The complement system is composed of over 30 proteins, activated in response to tissue injury, invading pathogens or other foreign surfaces. The complement pathways can be divided in the activation pathways and lytic pathway. The activation pathways lead via C3 to the cleavage of the fifth complement component C5. C5a was first described as a cleavage product of C5 with chemotactic and anaphylatoxic properties. Further characterization revealed that C5a is an essential part of the innate immune response and evidence now suggests that it may also play a role in adaptive immunity. Complement fragment C5a is a 74 residue pro-inflammatory polypeptide. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a binds to at least two seven-transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. The former is a well-established receptor that initiates G-protein-coupled signaling via mitogen-activated protein kinase pathways, thereby by inducing synthesis of cytokines such as TNF-alpha, IL-1beta, IL-6 and IL-8. Its in vivo blockade greatly reduces inflammatory injury. Much less is known about C5L2, occupancy of which by C5a does not initiate increased intracellular Ca(2+).The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases. Nowadays C5a is also implicated in non-immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis. The antibody 557 is capable to inhibit the binding of C5a to the C5a receptor through a competitive mechanism, it does not block the cleavage of C5 into C5a and C5b. Aliases CPAMD4, FLJ17816, FLJ17822, MGC142298 Immunogen BALB/c mice were immunized with human C5

Pathways: Système du Complément, Carbohydrate Homeostasis